Jennifer E. Amengual, MD
Dr. Amengual is an Assistant Professor of Medicine and Developmental Therapeutics and a member of the Center for Lymphoid Malignancies here at Columbia University. Her research goals are focused on developing targeted therapies for the treatment of lymphoma. As a physician-scientist, she aims to directly translate observations and concepts developed in the laboratory to patient care.
Dr. Amengual is concentrated on targeting the Bcl-6 : p53 pathway in diffuse large B-cell lymphoma (DLBCL) with histone deacetylase (HDAC) inhibitors in order to shift the balance of oncogene and tumor suppressor to enforce a less neoplastic phenotype. She is evaluating novel combinations of pan-class HDAC inhibitors with class III sirtuin inhibitors in DLBCL cell lines for mechanism of action and cytotoxicity, novel in vivo mouse models for efficacy and tolerability, and evaluating pharmacokinetics and pharmacodynamic endpoints in a proof-of-principle phase I clinical trial. By exploiting rational targeted therapy to the discrete signaling pathways known to cause DLBCL, she hopes to increase cure rates for those with lymphoma.